Status:
UNKNOWN
Tenofovir Alafenamide for HBV Prophylaxis in HBV(-) Liver Transplant Recipients With HBcAb+ Donors
Lead Sponsor:
RenJi Hospital
Conditions:
HBV
Liver Transplant Disorder
Eligibility:
All Genders
12+ years
Phase:
NA
Brief Summary
Liver transplantation is currently the only effective way to treat end-stage liver disease.The shortage of donor liver is still the major problem. Incidence of HBcAb+ varies between different regions....
Detailed Description
We intent to enroll 30 patients who are HBV negative but received HBcAb+ liver. Antiviral treatment with TAF(25mg/d,oral) will be started on the first day after liver transplantation. Post-operative H...
Eligibility Criteria
Inclusion
- Patients with written informed consent.
- Age ≥12 years old
- HBV negative recipients (HBV DNA undetectable and HBsAg negative) receiving HBsAg-, HBcAb+ donor liver
Exclusion
- Patients underwent liver re-transplantation
- CKD (CrCl\<30 ml/min by MDRD formula)
- HBV/HCV-related OLT
- Other solid organs transplant recipients
- HIV coinfection
Key Trial Info
Start Date :
April 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2024
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04703465
Start Date
April 1 2021
End Date
April 1 2024
Last Update
January 11 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.